GEN Exclusives

More »

GEN News Highlights

More »
Aug 1, 2012

Asterand Completes Move into Human Tissue Arena

  • Stemgent has sealed the deal for its acquisition of Asterand’s human tissue business for $9 million. Stemgent officials say Asterand’s human-tissue based tools for drug and target discovery complement its own portfolio of research products and services to advance cellular reprograming and stem cell studies.

    Stemgent’s offer for the Asterand unit was first announced in June. Asterand has been struggling with debt problems since it bought Bioseek, which develops human cell-based disease models, early in 2010 for $8.5 million. Asterand officials are in the process of deciding whether to sell Bioseek or let it operate as a stand-alone business.

    Ian Ratcliffe, president and CEO of Stemgent, labeled the Asterand acquisition as “an important step in our efforts to build a significant research tools business focused on human cells.” Asterand’s human tissue business includes the XpressBANK™ biobank and related services and PhaseZERO™ human tissue-based drug discovery research services. The human tissue and services operations will continue under the Asterand name. The combined organizations will have 100 employees with operations in the U.S. and U.K. Stemgent plans to retain Asterand’s operations in Detroit, MI, and in Royston, U.K.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »